An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Phase 2 Terminated 143 enrolled Genentech, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase Ib Study GA29469 (NCT02749630) and Phase II Study GA39925 (NCT03558152).

Timeline

Start: 2019-01-14
Primary completion: 2022-07-12
Completion: 2022-07-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efmarodocokin Alfa	Protein / enzyme biologic	—	—

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Summary

Timeline

Drugs

Indications